FDA Regulations on Investigational Peptides: The Legal Boundaries of Retatrutide & Semaglutide Sourcing

 

The online market for weight-loss peptides has exploded, but the legal boundaries governing these compounds are sharply defined and actively enforced. For researchers and procurement specialists, understanding the distinction between approved medications, compounded preparations, and unapproved new drugs is essential. Retatrutide and semaglutide occupy fundamentally different legal categories, and sourcing either through "research use only" channels carries significant regulatory risk.

Retatrutide: A Prohibited Compound

Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. As of September 2026, it has not been approved by the FDA for any indication and cannot be legally sold to consumers anywhere in the world.

The FDA has been unequivocal on this point. In a dedicated statement on unapproved GLP-1 drugs, the agency declared that "Retatrutide and cagrilintide cannot be used in compounding under federal law" because they are not components of FDA-approved drugs and have not been found safe and effective for any condition. This prohibition is absolute—there is no pathway for legal distribution outside of clinical trials.

The enforcement landscape reflects this clear legal position. Eli Lilly, the manufacturer, has filed six lawsuits against entities allegedly selling black-market retatrutide, including compounding pharmacies and online businesses marketing the drug as "research-use only". The company has referred over 200 individuals and entities to the FDA and law enforcement and reported more than 14,000 websites and social media posts unlawfully marketing retatrutide in over 100 countries.

The FDA has also issued multiple warning letters to online sellers. In September 2026, the agency sent warnings to Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and TXP Innovations for selling retatrutide and other unapproved peptides. A review of these websites found they all sold products under the pretence of "labourary research purposes only", yet the FDA determined from website evidence that the products were intended for human use—rendering the research-only disclaimer legally ineffective.

Semaglutide: Compounding Restrictions After Shortage Resolution

Semaglutide presents a more nuanced legal picture. The FDA-approved versions (Ozempic, Wegovy) are legal and available by prescription. However, the legal status of compounded semaglutide changed dramatically in February 2025 when the FDA determined the semaglutide injection shortage was resolved.

This determination triggered the end of enforcement discretion for compounders. Under the Federal Food, Drug, and Cosmetic Act, the law restricts compounding drugs that are "essentially copies" of commercially available FDA-approved drugs. When a drug shortage is resolved, the drug is generally considered commercially available, and the copy restriction applies.

The FDA established specific deadlines: state-licensed pharmacies under Section 503A could compound semaglutide until April 22, 2025, while outsourcing facilities under Section 503B had until May 22, 2025. After these dates, compounding semaglutide that is essentially a copy of the approved product violates federal law.

The FDA has reinforced this position through enforcement. The agency issued 25 warning letters in June 2026 alone to telehealth companies over misleading claims about compounded GLP-1 products. Common violations included suggesting compounded products were "generic" versions of approved drugs, implying FDA approval or review, and claiming the products were "clinically proven" to achieve the same results. Even technically accurate statements can render a product misbranded if the overall presentation is misleading under FDA's "net impression" framework.

The "Research Use Only" Loophole: Closed

The "research use only" designation has been a persistent feature of the grey-market peptide trade. Sellers routinely label products as "not for human consumption" to create apparent legal distance from drug regulations. The FDA has systematically rejected this tactic when website evidence demonstrates intended human use.

A 2024 warning letter to Prime Peptides illustrates the agency's approach. Despite labelling products for "research purposes only", the FDA-cited website claims that semaglutide "reduces cardiovascular events" and retatrutide "improves glycaemic control" as evidence establishing intended use as drugs for human consumption. The agency concluded the products were unapproved new drugs introduced into interstate commerce in violation of the FD&C Act.

This principle applies broadly: the legal status of a product depends on its intended use, not merely its label. When a vendor promotes weight loss, metabolic benefits, or any physiological effect, the "research only" disclaimer becomes legally meaningless.

Public Health Consequences

The regulatory prohibitions are not merely bureaucratic formalities. The FDA has received 990 adverse event reports associated with compounded semaglutide and more than 730 with compounded tirzepatide as of May 31, 2026. Unapproved injectable products bypass the body's natural defences when they enter the bloodstream directly, and their ingredients, purity, and sterility cannot be verified.

The legal boundaries are therefore clear and consistently enforced: retatrutide cannot be legally obtained outside clinical trials; compounded semaglutide is restricted following the shortage resolution; and "research use only" labelling does not provide legal protection when products are intended for human use. For procurement specialists, any vendor offering these compounds outside approved channels represents significant legal and safety risk.